Cresco Labs demonstrated strong operational performance and strategic foresight with key achievements in debt refinancing and market share maintenance. However, challenges such as revenue decline and price compression persist. The company is focusing on sustainable growth and profitability amidst industry-wide consolidation pressures.

Company Guidance

During the Cresco Labs Second Quarter 2025 earnings call, the company reported a revenue of $164 million, aligned with guidance and consistent with Q1 levels. The adjusted gross profit was $83 million, with an adjusted EBITDA of $41 million and operational cash flow of $9 million. The company highlighted its strategic focus on maintaining a solid balance sheet, announcing a refinancing of $325 million in debt to extend maturity to 2030, while paying down $35 million. This move is intended to enhance financial flexibility amid industry consolidation trends. Cresco Labs also emphasized its commitment to profitability and cash flow, with plans for expansion in core markets like Ohio, Kentucky, and Pennsylvania, and exploring M&A opportunities in New Jersey and Maryland. The company maintained strong market positions in Illinois and Pennsylvania, with a focus on operational efficiencies to counteract price compression. Despite anticipated margin drag in the latter half of the year due to initial harvest yields, Cresco remains optimistic about its strategic initiatives and long-term growth potential.

Debt Refinancing Secured

Cresco Labs secured a refinancing of $325 million of its debt, extending the maturity date to 2030 with a 12.5% interest rate. This provides enhanced financial flexibility at a time when capital is constrained in the U.S. cannabis sector.

Operational Strength and Market Share

Cresco Labs maintained #1 market share positions in Illinois and Pennsylvania and top 5 market shares in all limited licensed wholesale markets. Retail operations, such as Sunnyside, continue to outperform state averages by 20%.

Strategic Exits and Focused Growth

The company plans to exit the California market due to structural challenges while focusing on expanding in new markets like Ohio and Pennsylvania, where they lead in retail and branded product shares.

Strong Margins and Cost Management

Cresco Labs delivered a 51% adjusted gross margin, supported by operational efficiencies and a favorable product mix. Accounts receivable are down 23% since the start of the year.

Cash Flow and Profitability

Generated $9 million in operating cash flow with a cash balance of $147 million. The company continues to prioritize profitability and cash generation.

Cresco Labs (TSE:CL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:CL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 07, 2025	2025 (Q3)	-0.04 / -	-0.028	―	―	―
Aug 07, 2025	2025 (Q2)	-0.05 / -0.06	-0.204	72.79% (+0.15)
May 30, 2025	2025 (Q1)	-0.03 / -0.06	-0.014	-300.00% (-0.04)
Mar 12, 2025	2024 (Q4)	>-0.01 / 0.00	0.014	―
Nov 08, 2024	2024 (Q3)	0.01 / -0.03	-0.402	93.10% (+0.37)
Aug 08, 2024	2024 (Q2)	0.02 / -0.20	-0.147	-38.68% (-0.06)
May 15, 2024	2024 (Q1)	-0.03 / -0.01	-0.124	88.76% (+0.11)
Mar 13, 2024	2023 (Q4)	-0.03 / 0.01	-0.583	102.38% (+0.60)
Nov 15, 2023	2023 (Q3)	-0.06 / -0.40	-0.014	-2800.00% (-0.39)	―
Aug 16, 2023	2023 (Q2)	-0.07 / -0.15	-0.028	-430.00% (-0.12)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:CL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	C$0.93	C$0.96	+3.23%
May 30, 2025	C$0.93	C$0.84	-9.68%
Mar 12, 2025	C$1.07	C$1.06	-0.93%
Nov 08, 2024	C$1.75	C$1.73	-1.14%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cresco Labs OTC (TSE:CL) report earnings?

Cresco Labs OTC (TSE:CL) is schdueled to report earning on Nov 07, 2025, Before Open (Not Confirmed).

What is Cresco Labs OTC (TSE:CL) earnings time?

Cresco Labs OTC (TSE:CL) earnings time is at Nov 07, 2025, Before Open (Not Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSE:CL EPS forecast?

TSE:CL EPS forecast for the fiscal quarter 2025 (Q3) is -0.04.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing